| 0.0002 0 (0%) | 09-25 20:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.05 | 1-year : | 0.06 |
| Resists | First : | 0.05 | Second : | 0.05 |
| Pivot price | 0.05 | |||
| Supports | First : | 0.04 | Second : | 0.03 |
| MAs | MA(5) : | 0.05 | MA(20) : | 0.05 |
| MA(100) : | 0.05 | MA(250) : | 0.13  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 1 | D(3) : | 0 |
| RSI | RSI(14): 89.1 | |||
| 52-week | High : | 0.55 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ACUR ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 0.05 - 0.05 | 0.05 - 0.05 |
| Low: | 0.05 - 0.05 | 0.05 - 0.05 |
| Close: | 0.05 - 0.05 | 0.05 - 0.05 |
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.
Wed, 17 Sep 2025
Acura Pharmaceuticals Delays Quarterly Report Filing - MSN
Wed, 10 Sep 2025
Kelley Blue Book Report: August New-Vehicle Prices Rise as 2026 Models Hit Lots, EV Sales Accelerate - 富途牛牛
Thu, 04 Sep 2025
Acura Pharmaceuticals receives additional loans from AD Pharma, total debt rises to $8.7 million - Investing.com
Tue, 24 Jun 2025
Acura Pharmaceuticals receives $200,000 in new loans from AD Pharma - Investing.com
Wed, 23 Apr 2025
Acura Pharmaceuticals secures additional funding amid financial strain - Investing.com
Mon, 16 Aug 2021
Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 65 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 5.5 (%) |
| Held by Institutions | 3 (%) |
| Shares Short | 90 (K) |
| Shares Short P.Month | 76 (K) |
| EPS | -0.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | -0.47 |
| EPS Est Next Year | 0.37 |
| Book Value (p.s.) | 0 |
| Profit Margin | -51.3 % |
| Operating Margin | -49.4 % |
| Return on Assets (ttm) | -38.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -34.1 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.67 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 1.44 |
| Price to Cash Flow | -8.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|